Sarsia is an early-stage venture capital firm. We invest in a greener and healthier future.

News

Closeup of a woman looking through a microscope
Visit page

Portfolio

Bridge with sky as background
Visit page

Approach

Reliability is at the core of what we do

Visit page

Team

Background in science, experience from industry

Sarsia strenght lies in our differences; people with diverse backgrounds, knowledge and experience giving different perspectives.

Visit page

Investment areas

  • Life Sciences

    Our focus is on unmet medical needs. Where competence and capital are decisive when turning a laboratory result into an effective treatment for the patient.

    Visit page
  • Technology, Energy and Sustainability

    We search for technologies and founders capable of accelerating the green transition and of building sustainable companies for the future.

    Visit page

A talent for value creation begins with the will to dare the unknown

Theories, hypotheses and research are rooted in ambition. Clear goals, systematic hard work and dedication create results. Sarsia focus on technologies that can improve the quality of life, society and reduce negative impact on nature. Sarsia creates value by linking good solutions and science with competent capital. We thrive on change, and dare to take risks to create value. This has made us one of the best performing VC firms in the Nordic countries.

  • 18
    Years since startup
  • 1300
    mNOK (3 funds)
  • 12600
    mNOK Portfolio IPEV Value
  • 1417 companies screened

  • 28 portfolio companies

  • Top performance among Norwegian Early Stage Venture funds

  • Two of the most valuable early stage venture backed companies in Norway.

Latest news

  • Fri Feb 16 2024

    Sarsia is proud sponsor of WILD - Women in Life Science Norway

    Sarsia Management is proud to announce that we are among the first sponsors of the newly established

    Read full article
  • Wed Jan 24 2024

    Arxx merges with Oxitope and raises EUR 75 million in a Series A

    Arxx Therapeutics and Oxitope Pharma today announced their merger to form Calluna Pharma Inc. The n

    Read full article
  • Wed Oct 04 2023

    Pluvia Biotech appoints Willem van Weperen as new CEO

    Pluvia Biotech announces the appointment of Willem van Weperen as its new Chief Executive Officer (C

    Read full article